These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections. Elkashif A; Alhashimi M; Sayedahmed EE; Sambhara S; Mittal SK Clin Transl Immunology; 2021; 10(10):e1345. PubMed ID: 34667600 [TBL] [Abstract][Full Text] [Related]
3. Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines? Doerfler W Virus Res; 2021 Sep; 302():198466. PubMed ID: 34087261 [TBL] [Abstract][Full Text] [Related]
6. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
7. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. Folegatti PM; Jenkin D; Morris S; Gilbert S; Kim D; Robertson JS; Smith ER; Martin E; Gurwith M; Chen RT; Vaccine; 2022 Aug; 40(35):5248-5262. PubMed ID: 35715352 [TBL] [Abstract][Full Text] [Related]
10. Application of Traditional Vaccine Development Strategies to SARS-CoV-2. Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991 [TBL] [Abstract][Full Text] [Related]
11. Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors. Rzymski P Front Immunol; 2023; 14():1183258. PubMed ID: 37180147 [TBL] [Abstract][Full Text] [Related]
12. Viral vector and nucleic acid vaccines against COVID-19: A narrative review. Khoshnood S; Ghanavati R; Shirani M; Ghahramanpour H; Sholeh M; Shariati A; Sadeghifard N; Heidary M Front Microbiol; 2022; 13():984536. PubMed ID: 36118203 [TBL] [Abstract][Full Text] [Related]
13. Innovative translational platforms for rapid developing clinical vaccines against COVID-19 and other infectious disease. Wang N; Wang T Biotechnol J; 2024 Feb; 19(2):e2300658. PubMed ID: 38403469 [TBL] [Abstract][Full Text] [Related]
14. The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine. Sallard E; Zhang W; Aydin M; Schröer K; Ehrhardt A Viruses; 2023 Jan; 15(1):. PubMed ID: 36680244 [TBL] [Abstract][Full Text] [Related]
15. Insights from the Construction of Adenovirus-Based Vaccine Candidates against SARS-CoV-2: Expecting the Unexpected. Weklak D; Tisborn J; Mangold MH; Scheu R; Wodrich H; Hagedorn C; Jönsson F; Kreppel F Viruses; 2023 Oct; 15(11):. PubMed ID: 38005833 [TBL] [Abstract][Full Text] [Related]
16. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087 [TBL] [Abstract][Full Text] [Related]
17. mRNA Vaccines in the COVID-19 Pandemic and Beyond. Hogan MJ; Pardi N Annu Rev Med; 2022 Jan; 73():17-39. PubMed ID: 34669432 [TBL] [Abstract][Full Text] [Related]
18. Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. Kircheis R Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639132 [TBL] [Abstract][Full Text] [Related]